CASTLE BIOSCIENCES INC — Director's Dealing 2021

Jun 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CASTLE BIOSCIENCES INC (CSTL)
CIK: 0001447362
Period of Report: 2021-06-15

Reporting Person: Stokes Frank (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-15	Common Stock	M	11600	$2.39	Acquired	17520	Direct
2021-06-15	Common Stock	S	11600	$73.02	Disposed	5920	Direct
2021-06-16	Common Stock	M	2127	$2.39	Acquired	8047	Direct
2021-06-16	Common Stock	S	2127	$73.07	Disposed	5920	Direct
2021-06-17	Common Stock	M	1273	$2.39	Acquired	7193	Direct
2021-06-17	Common Stock	S	1273	$73	Disposed	5920	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-15	Stock option (right to buy)	$2.39	M	11600	Disposed	2028-05-09	Common Stock (11600.0)	Direct
2021-06-16	Stock option (right to buy)	$2.39	M	2127	Disposed	2028-05-09	Common Stock (2127.0)	Direct
2021-06-17	Stock option (right to buy)	$2.39	M	1273	Disposed	2028-05-09	Common Stock (1273.0)	Direct

Footnotes

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 14, 2021.

F2: Includes 2,034 shares acquired on February 26, 2021 under the Issuer's employee stock purchase plan.

F3: This transaction was executed in multiple trades at prices ranging from $73.00 to $73.13, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $73.00 to $73.33, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.